Crinetics Pharmaceuticals, Inc.
CRNX
$46.98
$1.974.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 47.74% | 0.51% | -61.50% | -74.11% | -78.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.74% | 0.51% | -61.50% | -74.11% | -78.00% |
| Cost of Revenue | 42.97% | 41.20% | 17.89% | 14.70% | 7.74% |
| Gross Profit | -42.95% | -41.57% | -18.75% | -16.87% | -10.35% |
| SG&A Expenses | 87.07% | 78.25% | 71.48% | 71.68% | 69.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.74% | 51.95% | 50.92% | 49.98% | 45.04% |
| Operating Income | -55.77% | -52.21% | -51.81% | -52.22% | -47.84% |
| Income Before Tax | -52.24% | -43.05% | -39.41% | -39.10% | -39.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.24% | -43.05% | -39.41% | -39.10% | -39.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.24% | -43.05% | -39.41% | -39.10% | -39.36% |
| EBIT | -55.77% | -52.21% | -51.81% | -52.22% | -47.84% |
| EBITDA | -55.71% | -51.93% | -51.29% | -51.72% | -47.54% |
| EPS Basic | -21.96% | -9.10% | -1.20% | -0.12% | -2.14% |
| Normalized Basic EPS | -21.97% | -9.09% | -1.20% | -0.11% | -2.14% |
| EPS Diluted | -21.96% | -9.10% | -1.20% | -0.12% | -2.14% |
| Normalized Diluted EPS | -21.97% | -9.09% | -1.20% | -0.11% | -2.14% |
| Average Basic Shares Outstanding | 24.81% | 30.24% | 37.19% | 39.09% | 36.42% |
| Average Diluted Shares Outstanding | 24.81% | 30.24% | 37.19% | 39.09% | 36.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |